Abbvie-Header Abbvie-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mazindol

            Therapeutic Area: Psychiatry/Psychology Product Name: Quilience

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: NLS Pharmaceutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 12, 2021

            Details:

            Agreement provides exclusive rights to all available data included in the original new drug application for mazindol in the U.S. Mazindol is a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, used for to treat narcolepsy in compassionate use programs.